Mobile official website
Yantai Huaxin Biomedical Science and Technology Co., Ltd
Our company was approved by Yantai City's 2019 Key R&D Plan Project
Recently, the Yantai Municipal Science and Technology Bureau announced the proposed project of the Yantai Key Research and Development Plan in 2019. The project "Research on the Effective Material Basis and Mechanism of the Classic Chinese Medicine Gentiana against Rheumatoid Arthritis" jointly declared by Yantai University and our company was approved. As a key research and development plan, the project number is "2019XDHZ109". The project is led by Yantai University. Our company is a cooperative unit to cooperate with the development of related research work. Dr. Hou Jian participates in the research and development of the project as the company's project leader.
On November 16, 2017, our company signed a practical teaching base agreement with the School of Pharmacy of Yantai University. Since the signing of the agreement, our company and the School of Pharmacy of Yantai University have been closer to combine teaching and production. Our school and enterprise support each other , Mutual penetration, two-way intervention, complementary advantages, mutual use of resources, and benefit sharing have realized the rational integration of college education and modern enterprise management.
Rheumatoid arthritis (RA) is a chronic, inflammatory synovitis-based systemic disease of unknown etiology. It is characterized by multiple joints, symmetry, and aggressive joint inflammation of the small joints of the hands and feet. Accompanied by involvement of extra-articular organs and positive serum rheumatoid factor, it can lead to joint deformities and loss of function. It belongs to the category of "Bizheng" in traditional Chinese medicine and is one of the clinically refractory diseases. The onset of RA may be related to heredity, infection, sex hormones and so on. In recent years, a large number of experimental researches have been carried out on the anti-RA effects of natural drugs at home and abroad, mainly in antibacterial, anti-inflammatory, analgesic and immune regulation.
The successful establishment of this project reflects the government's emphasis on medical care and health in recent years. For a long time, our company has focused on serving the country's major strategic needs, strengthened the research and development of key common technologies in the health industry, and promoted the integration of production, education and research and the transformation of scientific and technological achievements. And through school-enterprise cooperation, collaborative innovation brings together new momentum for scientific research, seamlessly connecting the innovation chain and the industrial chain, forming a benign interactive development of talents, scientific research, and industrialization, providing strong support for the development of the national economy. The establishment of Yantai’s key R&D project has greatly boosted our company’s confidence in continuing to carry out high-level scientific research, and will play a positive role in further enhancing our company’s scientific and technological competitiveness, promoting the transformation of scientific and technological achievements, and serving the revitalization of the society.